Unknown

Dataset Information

Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?


ABSTRACT:

Purpose of review

The majority of patients with non-small cell lung cancer (NSCLC) present with advanced disease and overall survival rates are poor. This article outlines the current and outstanding evidence for the use of multimodality treatment in this group of patients, including in combination with an increasing number of treatment options, such as immunotherapy and genotype-targeted small molecule inhibitors.

Recent findings

Optimal therapy for surgically resectable stage III disease remains debatable and currently the choice of treatment reflects each individual patient's disease characteristics and the expertise and opinion of the thoracic multi-disciplinary team. Evidence for a distinct oligometastatic state in which improved outcomes can be achieved remains minimal

SUBMITTER: Jones CM 

PROVIDER: S-EPMC5805813 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature